Monitoring of Donor-specific Antibodies After Treatment with Immunoglobulins, Plasmapheresis and Rituximab in Lung Transplantation

Hannover Medical School (MHH)

Status: Enrolling

Conditions: Donor-specific Anti-human Leukocyte Antigen(HLA) Antibodies; Lung Transplantation

Treatments: Diagnostic Test: blood samples

Study type: Observational

Funder types: Other

Identifiers

NCT03798860

DSA-2018

Details and patient eligibility

About

Single-arm, prospective observational study

Full description

This is an observational study to monitor the treatment of donor-specific antibodies in lung transplant recipients with detection of donor-specific antibodies. All consented subjects will be approached for participation. The study will evaluate the effectiveness of the treatment protocol of donor-specific antibodies with Immunoglobulins or combined treatment with Immunoglobulins, Plasmapheresis and Rituximab after lung transplantation.

Enrollment: 75 estimated patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• all patients after lung transplantation with detection of donor-specific antibodies

Exclusion criteria

• none